Abstract
The significance of low-dose total body irradiation (TBI) in HLA-mismatched reduced-intensity conditioning stem cell transplantation (RICT) remains unknown. We, retrospectively, evaluated the impact of low-dose TBI in patients with hematological malignancies who received first RICT from ≥1 antigen-mismatched donors between 2004 and 2014. Of the 575 patients, 361 patients received low-dose TBI (2 or 4 Gy). There were no significant differences in neutrophil engraftment or platelet recovery between TBI and non-TBI groups. The benefit of low-dose TBI on neutrophil engraftment was not observed in any subgroups. Low-dose TBI was not associated with decreased secondary graft failure. Suppressed mixed chimerism and autologous hematopoiesis by low-dose TBI was observed. There were no significant differences in cumulative incidences of acute GVHD or nonrelapse mortality rates in either group; however, low-dose TBI improved overall survival (OS), especially in patients with high-risk disease, multi-HLA mismatch, and fludarabine/busulfan conditioning. Multivariate analysis demonstrated that low-dose TBI was an independent prognostic factor for OS. Compared with the non-TBI group, 4 Gy TBI, but not 2 Gy TBI, was associated with increased acute GVHD and reduced relapse. These findings suggest that low-dose TBI may be beneficial for patients at high risk for relapse in HLA-mismatched RICT.
| Original language | English |
|---|---|
| Journal | Bone Marrow Transplantation |
| DOIs | |
| Publication status | Accepted/In press - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation. / on behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.
In: Bone Marrow Transplantation, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation
AU - on behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Fujiwara, Shin ichiro
AU - Kanda, Junya
AU - Tatara, Raine
AU - Ogawa, Hiroyasu
AU - Fukuda, Takahiro
AU - Okumura, Hirokazu
AU - Ohashi, Kazuteru
AU - Iwato, Koji
AU - Ueda, Yasunori
AU - Ishiyama, Ken
AU - Eto, Tetsuya
AU - Matsuoka, Ken-ichi
AU - Nakamae, Hirohisa
AU - Onizuka, Makoto
AU - Atsuta, Yoshiko
AU - Kanda, Yoshinobu
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The significance of low-dose total body irradiation (TBI) in HLA-mismatched reduced-intensity conditioning stem cell transplantation (RICT) remains unknown. We, retrospectively, evaluated the impact of low-dose TBI in patients with hematological malignancies who received first RICT from ≥1 antigen-mismatched donors between 2004 and 2014. Of the 575 patients, 361 patients received low-dose TBI (2 or 4 Gy). There were no significant differences in neutrophil engraftment or platelet recovery between TBI and non-TBI groups. The benefit of low-dose TBI on neutrophil engraftment was not observed in any subgroups. Low-dose TBI was not associated with decreased secondary graft failure. Suppressed mixed chimerism and autologous hematopoiesis by low-dose TBI was observed. There were no significant differences in cumulative incidences of acute GVHD or nonrelapse mortality rates in either group; however, low-dose TBI improved overall survival (OS), especially in patients with high-risk disease, multi-HLA mismatch, and fludarabine/busulfan conditioning. Multivariate analysis demonstrated that low-dose TBI was an independent prognostic factor for OS. Compared with the non-TBI group, 4 Gy TBI, but not 2 Gy TBI, was associated with increased acute GVHD and reduced relapse. These findings suggest that low-dose TBI may be beneficial for patients at high risk for relapse in HLA-mismatched RICT.
AB - The significance of low-dose total body irradiation (TBI) in HLA-mismatched reduced-intensity conditioning stem cell transplantation (RICT) remains unknown. We, retrospectively, evaluated the impact of low-dose TBI in patients with hematological malignancies who received first RICT from ≥1 antigen-mismatched donors between 2004 and 2014. Of the 575 patients, 361 patients received low-dose TBI (2 or 4 Gy). There were no significant differences in neutrophil engraftment or platelet recovery between TBI and non-TBI groups. The benefit of low-dose TBI on neutrophil engraftment was not observed in any subgroups. Low-dose TBI was not associated with decreased secondary graft failure. Suppressed mixed chimerism and autologous hematopoiesis by low-dose TBI was observed. There were no significant differences in cumulative incidences of acute GVHD or nonrelapse mortality rates in either group; however, low-dose TBI improved overall survival (OS), especially in patients with high-risk disease, multi-HLA mismatch, and fludarabine/busulfan conditioning. Multivariate analysis demonstrated that low-dose TBI was an independent prognostic factor for OS. Compared with the non-TBI group, 4 Gy TBI, but not 2 Gy TBI, was associated with increased acute GVHD and reduced relapse. These findings suggest that low-dose TBI may be beneficial for patients at high risk for relapse in HLA-mismatched RICT.
UR - http://www.scopus.com/inward/record.url?scp=85060533111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060533111&partnerID=8YFLogxK
U2 - 10.1038/s41409-019-0434-3
DO - 10.1038/s41409-019-0434-3
M3 - Article
C2 - 30670824
AN - SCOPUS:85060533111
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
ER -